Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
MRTX.US
id: 875
Mirati (MRTX) M&A Case
D. Delaware
Court1:23-cv-01297
Case number- Bristol-Myers said it would acquire Mirati for $58.00 in cash per share plus $12.00 CVR.
- Before the deal, analyst targets were higher than the offered price.
- The lawsuit alleges that the proposed $MRTX sale price undervalues the company.
On October 8, 2023, Bristol-Myers Squibb announced it would acquire Mirati Therapeutics for up to $5.8 billion.
- The deal offers Mirati shareholders $58.00 in cash per share, and
- Contingent Value Right, which would grant an extra $12.00 in cash if the FDA accepts the NDA of MRTX1719 for specific treatment criteria within seven years post-merger.
Just before the proposed deal, investment banks' targets were higher than the acquisition price, analysts from Barclays forecasted $71, Leerink - $78, and Stifel - $83.
Taking all facts into account, investors have reasons to suspect that this deal underestimates $MRTX's full and fair value.
Case Status
Attorney Investigation
Alleged Offence
Mismanagement,
Financial Misrepresentation,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
07 November 2023
Filing date
14 November 2023